Cardiovascular Risk Factors in Hypertension: Rationale and Design of Studies to Investigate the Effects of Controlled-Release Carvedilol on Regression of Left Ventricular Hypertrophy and Lipid Profile
Authors:
- George L. BakrisGBGeorge L. Bakris
- Elizabeth A. TarkaETElizabeth A. Tarka
- Brian WaterhouseBWBrian Waterhouse
- Michelle R. GouldingMGMichelle R. Goulding
- Anuradha MadanAMAnuradha Madan
- Karen M. AndersonKAKaren M. Anderson
- 2 October 2006
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 98 (7) , 46-52
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Renal Protection in Hypertensive Patients: Selection of Antihypertensive TherapyDrugs, 2005
- Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A randomized controlled trial.JAMA, 2004
- Managing the patient with diabetes mellitus and heart failure: issues and considerationsThe American Journal of Medicine, 2004
- Use of Beta Blockers in the Patient With DiabetesThe Endocrinologist, 2003
- The Treatment of Hypertension in Adult Patients With DiabetesDiabetes Care, 2002
- Preserving renal function in adults with hypertension and diabetes: A consensus approachAmerican Journal of Kidney Diseases, 2000
- Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy∗∗∗∗A list of participating hospitals, central agencies and personnel appears in reference 26.JACC, 2000
- Is There a Role for Beta‐blockers in Hypertensive Diabetic Patients?Diabetic Medicine, 1994
- The pharmacology of carvedilolEuropean Journal of Clinical Pharmacology, 1990
- Left Ventricular HypertrophyDrugs, 1988